10 results match your criteria: "Central Cardiology Medical Clinic[Affiliation]"
J Soc Cardiovasc Angiogr Interv
August 2023
Inova Heart and Vascular Institute, Falls Church, Virginia.
Background: How diabetes mellitus (DM), race/ethnicity, and sex impact ischemic events following coronary artery stent procedures is unknown.
Methods: Using the PLATINUM Diversity and PROMUS Element Plus Post-Approval Pooled Study (N = 4184), we examined the impact of race/ethnicity, sex, and DM on coronary stent outcomes. Primary outcome was 1-year major adverse cardiac events (MACE) (MACE composite: death, myocardial infarction [MI], and target vessel revascularization).
Am J Cardiol
August 2023
The Zena and Michael A. Wiener Cardiovascular Institute, The Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address:
There is limited data on new-generation stent outcomes in patients with previous coronary artery bypass graft (CABG) and the associated risk of gender and race/ethnicity is unclear. We investigated 1-year outcomes after platinum chromium everolimus-eluting stent implantation in a diverse population of men, women, and minorities with previous CABG pooled from the PLATINUM Diversity (NCT02240810) and PROMUS Element Plus (NCT01589978) registries. Our primary outcome was major adverse cardiac events (MACE), a composite of all-cause death, myocardial infarction (MI), and target vessel revascularization (TVR) at 1-year post percutaneous coronary intervention (PCI).
View Article and Find Full Text PDFCatheter Cardiovasc Interv
July 2019
Tallahassee Memorial Healthcare, Tallahassee, Florida.
Objective: We evaluated 1-year outcomes after platinum chromium everolimus-eluting stents (PtCr-EES) in small versus non-small coronary arteries within a large, diverse sample of men, women, and minorities.
Background: There exists limited outcomes data on the use of second-generation drug-eluting stent to treat small diameter coronary arteries.
Methods: We pooled patients from the PLATINUM Diversity and PROMUS Element Plus stent registries.
Importance: There exist limited outcomes data for women and minorities after contemporary percutaneous coronary intervention (PCI).
Objective: To examine 1-year outcomes in women and minorities vs white men after PCI with everolimus-eluting stents.
Design, Settings, And Participants: The PLATINUM Diversity study was a single-arm study enrolling women and minorities.
J Cardiovasc Pharmacol Ther
March 2003
Central Cardiology Medical Clinic, Bakersfield, CA 93301, USA.
We describe two cases of intracoronary vascular brachytherapy where bivalirudin (Angiomax), employed as an anticoagulant, led to abrupt vessel closure or threatened abrupt closure. Use of bivalirudin (Angiomax) during intracoronary brachytherapy may predispose to the formation of intracoronary thrombus, related to the reversible binding kinetics of the bivalirudin to thrombin, and resulting in recovery of thrombin functional activity during periods of prolonged stasis that occur during intracoronary brachytherapy. Intracoronary abciximab administration may be a useful strategy in resolving the acute closure, since abciximab administered early during the formation of thrombus has been shown to facilitate clot lysis.
View Article and Find Full Text PDFJ Cardiovasc Pharmacol Ther
January 2002
Central Cardiology Medical Clinic and Bakersfield Heart Hospital, 2110 Truxtun Avenue, Bakersfield, CA 93301, USA.
A case of a 65-year-old woman presenting with delayed profound thrombocytopenia 7 days after the use of abciximab (ReoPro) in the setting of percutaneous coronary intervention is described. The patient had normal platelet counts for the first 24 hours after the use of abciximab (ReoPro). She presented with petechiae and profound thrombocytopenia 1 week later.
View Article and Find Full Text PDFAm J Cardiol
January 1996
Central Cardiology Medical Clinic, Los Angeles, California, USA.
Transthoracic echocardiography combined with transesophageal atrial pacing was performed in a community outpatient setting and compared with single-photon emission computed tomography (SPECT) and with coronary arteriography to determine the accuracy and usefulness of the technique. Two groups were defined: group A consisted of 65 of 189 patients who underwent all 3 procedures within a 90-day period; group B consisted of 53 patients who had atrial pacing with transthoracic echocardiography. Seventy-one patients had previously undergone atrial pacing with simultaneous transesophageal echocardiography.
View Article and Find Full Text PDFAm Heart J
December 1991
Central Cardiology Medical Clinic, Bakersfield, CA 93301.
Intravenous amiodarone was administered to 22 patients with recurrent ventricular tachycardia failing an average of 3.0 prior antiarrhythmic agents after a mean of 14.6 cardioversions per patient.
View Article and Find Full Text PDFThe role of the signal-averaged ECG was prospectively assessed in 517 patients in whom there was a suspicion for malignant ventricular arrhythmias. Patients were divided into Group I with a normal surface QRS width less than 120 ms (426 patients) and Group II with a prolonged QRS duration greater than or equal to 120 ms (91 patients). Late potentials were present in 42 (10%) Group I patients and in 24 (26%) Group II patients.
View Article and Find Full Text PDFPacing Clin Electrophysiol
September 1990
Central Cardiology Medical Clinic, Bakersfield, California 93301.
False inhibition of ventricular output due to spurious signals from a bipolar Oscor Medical lead (PY58BV) is reported following implantation of a Pacesetter Synchrony DDDR 2020T. Telemetered bipolar and distal unipolar intracardiac electrograms revealed 20 mV spurious signals coming from the distal screw-in electrode. Reprogramming the sensing channel to unipolar ring prevented inhibition of pacemaker output.
View Article and Find Full Text PDF